immunoglobulin heavy constant gamma 4 (G4m marker)Genealiases: []
Q-omics provides the consensus-scored IGHG4 profile across patient tissues and cancer cell-line models. IGHG4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGHG4 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, IGHG4 protein abundance shows 14,439 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, LUAD, and GBM as cancer lineages where IGHG4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHG4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHG4 survival associations across molecular data types. IGHG4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHG4 RNA expression–survival associations across cancer types. High IGHG4 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, SKCM, UCS, READ and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGHG4 RNA expression.
This table summarizes IGHG4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IGHG4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHG4 shows lower tumor expression in LIHC and higher tumor expression in LUAD, HNSC, STAD, BRCA and COAD. The LUAD box plot shows higher IGHG4 RNA expression in tumor versus normal tissue (log2 FC = +3.369, t-test p < 0.001).
This table shows molecular features associated with IGHG4 in patient tissues and cancer cell lines. In patient samples, IGHG4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGHG4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
